5-Amino-1MQ

Overview

5-Amino-1MQ represents a different class of metabolic compound than most peptides on this site — it’s a small molecule rather than a peptide — but it’s gained significant traction in the research community for its fat loss potential. The mechanism is distinct from GLP-1 agonists or growth hormone secretagogues: rather than suppressing appetite or stimulating hormones, it works upstream at the enzyme level by preserving NAD+ precursors.

The compound is an NNMT inhibitor. NNMT (nicotinamide N-methyltransferase) is an enzyme that methylates nicotinamide, routing it away from NAD+ synthesis. NNMT is overexpressed in obese adipose tissue, which is thought to contribute to metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ essentially redirects nicotinamide back toward NAD+ production, triggering downstream metabolic changes in fat cells.

Preclinical Evidence

The most cited study (Neelakantan et al., 2019) demonstrated ~7-8% body weight reduction in diet-induced obese mice over three weeks of treatment — without changing food intake or activity levels. Notably, the weight lost was predominantly fat mass, with lean mass preserved. Adiponectin (an insulin-sensitizing hormone) increased significantly.

Additional studies have confirmed the adipogenesis-inhibiting effect in vitro: pre-adipocytes exposed to 5-Amino-1MQ showed significantly reduced differentiation into mature fat cells. The proposed mechanism involves an increase in the SAM/SAH (S-adenosylmethionine to S-adenosylhomocysteine) ratio, which creates epigenetic changes that suppress lipogenic gene expression.

The NAD+ Connection

One reason 5-Amino-1MQ attracts interest in longevity circles is its relationship to NAD+ biology. By blocking nicotinamide degradation, it effectively acts as an upstream NAD+ booster — potentially synergistic with direct NAD+ precursor supplementation (NMN, NR). Whether this translates to meaningful sirtuin activation in humans at practical doses remains unconfirmed, but the mechanistic rationale is sound.

Human Data Gap

The honest limitation: essentially no peer-reviewed human clinical data exists as of mid-2026. The compound is available as a research chemical and has accumulated substantial anecdotal use (particularly in the body composition community), but there are no Phase I/II trials establishing safety, pharmacokinetics, or efficacy in humans. This is the primary reason it remains research-only.

Anecdotal reports from the research community typically describe:

• Increased warmth/thermogenesis (consistent with enhanced fat oxidation)
• Noticeable fat loss over 4–8 weeks at 50–100 mg/day
• Good tolerability with no commonly reported serious adverse effects

These reports should be interpreted cautiously — they are not a substitute for clinical evidence.

Dosing Considerations

Most research protocols reference 50–100 mg/day oral dosing, often with a cycling pattern (5 days on, 2 days off). The half-life in animal models is relatively short (~2–4 hours), which has led some protocols to split the dose. No pharmacokinetic data in humans has been published.

The compound is typically sourced as a powder and encapsulated, or purchased as pre-made capsules from research chemical suppliers. Quality and purity vary significantly by source.

Bottom Line

5-Amino-1MQ has a genuinely interesting mechanism and compelling preclinical data. The fat loss results in animal models are hard to ignore. But the absence of human trials means the translation to human physiology is unconfirmed, and long-term safety is unknown. It warrants attention as preclinical data matures, but should not be treated as an established intervention.